We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Blood Test Could Predict Multiple Sclerosis Progression

By LabMedica International staff writers
Posted on 01 Jul 2020
Print article
Image: The NF-light (Neurofilament light) ELISA kit allows fast quantification in less than three hours of neurofilament light in cerebrospinal fluid (Photo courtesy of Andreas Nilsson).
Image: The NF-light (Neurofilament light) ELISA kit allows fast quantification in less than three hours of neurofilament light in cerebrospinal fluid (Photo courtesy of Andreas Nilsson).
Multiple sclerosis (MS) is an immune-mediated neurodegenerative disease of the central nervous system (CNS), with a highly variable inter-individual disease course. As a result, even if using existing clinical prognostic factors, the forecasting of long-term prognosis is often unreliable and imprecise.

Neurofilaments provide structural support to axons as the main component of the neuronal cytoskeleton. Elevated levels of these proteins have been observed in several neurodegenerative diseases. In persons with MS, elevated CSF levels of neurofilament light chain (NfL) or heavy chain have been associated with brain atrophy and long-term outcome.

Neurologists at the Karolinska Institutet (Stockholm, Sweden) and their associates investigated the association between plasma neurofilament light chain (pNfL) levels and the risk of developing sustained disability worsening. They enrolled 4,385 individuals with MS and randomly selecting 1,026 people matched for age and sex who did not have MS.

The team used the highly sensitive Single Molecule Array (Simoa, Billerica, MA, USA) NF-Light Advantage Kit, with antibodies from UmanDiagnostics (Umeå, Sweden). They assessed the impact of age-stratified pNfL levels above the 80th, 95th, and 99th percentiles among controls on the risk of Expanded Disability Status Scale (EDSS) worsening within the following year and reaching sustained EDSS scores of 3.0, 4.0, and 6.0 and conversion to secondary progressive multiple sclerosis (SPMS).

The investigators reported that the participants were followed for a total of five years to see if they developed increased levels of disability. They also looked to see if individuals with high NfL levels developed secondary progressive multiple sclerosis (SPMS). MS patients had an average NfL level of 11.4 pg/mL compared to 7.5 pg/mL in the non-MS patients.

Overall, investigators determined that high plasma NfL correlated with sustained EDSS scores 3.0 and 4.0. MS patients were 40% to 70% more likely to have worsening disability during the following year and 50% more likely to reach a level of moderate disability that affected daily activities. The results reflect other variables that could affect the risk of poorer outcomes in the MS patients, such as rate of relapse and longevity of disease. A total of 525 MS patients (16%) reached the moderate level of disability, and 352 patients (9%) reached significant disability.

Ali Manouchehrinia, PhD, an assistant professor and first author of the study, said, “These results suggest that elevated levels of these nerve proteins biomarkers measured early on in the course of the disease may help us to predict how the disease will develop and monitor how treatment is working. In a disease like MS that is so unpredictable and varies so much from one person to the next, having a noninvasive blood test like this could be very valuable, especially since treatments are most effective in the earliest stages of the disease.”

The authors concluded that elevated pNfL levels measured early on in the disease course are associated with an increased risk of reaching sustained disability milestones. Hence, pNfL may serve as a prognostic and treatment monitoring tool to assess the risk of developing permanent disability in MS as part of a more standardized, noninvasive, longitudinally accessible, and generalizable approach. The study was published on June 9, 2020 in the journal Neurology.

Related Links:
Karolinska Institutet
Simoa
UmanDiagnostics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.